Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease
Status:
Completed
Trial end date:
2017-11-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety of BCT197 when added on to
standard of care in adult subjects with acute respiratory exacerbations of chronic
obstructive pulmonary disease requiring hospitalization. Additionally, the study will
characterize the pharmacokinetics of BCT197 in adults with COPD. The total duration of the
study will be 26 weeks. Subjects will receive study treatment administration over a period of
5 days after randomization. It is expected that approximately 255 subjects will complete the
study and follow-up.